Translating experimental neuroscience into treatment of eating disorders: Two examples

Section of Eating Disorders, King's College London, Institute of Psychiatry, De Crespigny Park, London SE5 8AF, UK.
Current Topics in Behavioral Neurosciences 01/2011; 6(1):253-68. DOI: 10.1007/7854_2010_76
Source: PubMed


Anorexia nervosa (AN) is a serious mental disorder with impaired functioning including not only the cognitive and socio-emotional but also physical domains. Improved treatments, especially for adults with AN, are urgently needed. The insights gained from basic research in experimental animal models and the advent of cognitive neuroscience have produced major advances in our understanding of the condition, but translating these into clinical research or practice remains a challenge. We describe here what the eating disorders field can gain from schizophrenia research in this area. We use the example of socio-emotional impairments in AN to describe the iterative process between basic research and intervention development for neurobiologically informed and based treatments for this condition and briefly touch on some other examples that stem from translational science.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: FDA approval of Belviq and Qsymia seems to suggest that novel pharmacological targets to modulate human abnormal eating behaviours are still to be identified. However, a renewed translational approach opens new avenues on eating disorders and female vulnerability, highlighting the role of our reward pathway in obesity and binge eating and leading to potential novel targets. Nevertheless, the 'food addiction' hypothesis is still causing much scientific debate. In this context the interest in the modulation of ghrelin pathway is still very high although, so far, only ghrelin agonism has confirmed its therapeutic potential in cachectic patients. Unfortunately, ghrelin modulation does not offer a therapeutic option for Anorexia Nervosa, where novel promising pharmacological treatments are still to be uncovered.
    Current Opinion in Pharmacology 02/2014; 14C(1):1-5. DOI:10.1016/j.coph.2013.09.015 · 4.60 Impact Factor